BUDAPEST, Hungary and LONDON and PRINCETON, New Jersey, July 16 /PRNewswire/ -- ThalesNano Inc. today announced, that within three years from the original introduction of its H-Cube product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.
The H-Cube(R) Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation reactor, uniquely combining continuous-flow chemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. It allows safe, fast and cost-efficient hydrogenation with superior yield when compared to conventional methods. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shorted development time, increased cost efficiency and reduced environmental impact.
"Having all of the top 20 pharmaceutical companies as H-Cube users is a real testimony that the instrument is changing the process of how drugs are developed and the benefits that can be derived as a result", said Dr. Laszlo Urge, CEO of ThalesNano Inc. "Our early customers are now using our technology at multiple sites on four continents. H-Cube has become their first line of technology for catalytic hydrogenations. After establishing our continuous process technology in the discovery labs of the life sciences industry we are moving into the early scale up and full production with the new versions of the systems."
Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "It is clear that our strategy of providing a disruptive technology to the industry is working. The benefits of these technologies over conventional batch chemistry include the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include "Green Chemistry" by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market."
For more information please go to: http://www.thalesnano.com
About ThalesNano Inc.:
ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.
Contact: Laszlo Urge, Ph.D., CEO, e-mail: firstname.lastname@example.org, Telephone: +36-1-880-8500
|SOURCE ThalesNano Nanotechnology Inc|
Copyright©2008 PR Newswire.
All rights reserved